COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE CHECKPOINT INHIBITOR THERAPY
Provided herein are compositions and methods for treating cancer, treating colitis associated with immune checkpoint inhibitor therapy, colonizing the microbiome, and/or restoring the microbiome, by administering compositions or food products to a subject.
1 . A composition comprising Eubacterium limosum, Subdolinogranulum sp., Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevotella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
2 . A composition comprising Fusobacterium ulcerans, Eubacterium limosum, Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevoella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
3 . A composition comprising Eubacterium limosum, Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevoella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
4 . A composition comprising Fusobacterium ulcerans, Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevoella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
5 . A composition comprising Fusobacterium ulcerans, Subdolinogranulum sp., Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevoella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
6 . A composition consisting of Eubacterium limosum, Subdolinogranulum sp., Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevotella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
7 . A composition consisting of Fusobacterium ulcerans, Eubacterium limosum, Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevoella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
8 . A composition consisting of Eubacterium limosum, Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevoella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
9 . A composition consisting of Fusobacterium ulcerans, Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevoella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
10 . A composition consisting of Fusobacterium ulcerans, Subdolinogranulum sp., Phascolarctobacterium faecium, Parabacteriodes johnsonii, Paraprevoella xylaniphila, Parabacteroides distasonis, Alistipes sp., Bacteroides dorei, Parabacteroides gordonii , and Bacteroides uniformis.
11 . A composition comprising a purified bacterial mixture comprising bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1 and 3-11.
12 . A composition comprising a purified bacterial mixture comprising bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1-4 and 6-11.
13 . A composition comprising a purified bacterial mixture comprising bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1, 3, 4, and 6-11.
14 . A composition comprising a purified bacterial mixture comprising bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1-4, 6-9, and 11.
15 . A composition comprising a purified bacterial mixture comprising bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1-9 and 11.
16 . A composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1 and 3-11.
17 . A composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1-4 and 6-11.
18 . A composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1, 3, 4, and 6-11.
19 . A composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1-4, 6-9, and 11.
20 . A composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs: 1-9 and 11.
21 . The composition of any one of claims 1 - 20 , wherein the composition is effective in enhancing immune checkpoint inhibitor therapy.
22 . The composition of any one of claims 1 - 21 , wherein the composition is effective in treating colitis associated with checkpoint inhibitor therapy.
23 . The composition of any one of claims 1 - 22 , wherein the composition is effective in inducing the production of regulatory T cells (Tregs) in the intestine.
24 . The composition of any one of claims 1 - 23 , wherein the composition is effective in inducing the production of IFNγ+ CD8+ T cells in the intestine.
25 . The composition of any one of claims 1 - 24 , wherein the bacterial strains are lyophilized.
26 . The composition of any one of claims 1 - 25 , wherein the bacterial strains are spray-dried.
27 . The composition of any one of claims 1 - 26 , wherein one or more of the bacterial strains are in spore form.
28 . The composition of any one of claims 1 - 27 , wherein each of the bacterial strains is in spore form.
29 . The composition of any one of claims 1 - 27 , wherein one or more of the bacterial strains are in vegetative form.
30 . The composition of any one of claim 1 - 26 or 29 , wherein each of the bacterial strains is in vegetative form.
31 . The composition of any one of claims 1 - 30 , wherein the composition further comprises one or more anticancer agents.
32 . The composition of claim 31 , wherein the anticancer agent is a chemotherapy agent.
33 . The composition of claim 32 , wherein the anticancer agent is a cancer immunotherapy agent.
34 . The composition of claim 33 , wherein the cancer immunotherapy agent is an immune checkpoint inhibitor.
35 . The composition of claim 34 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor, PD-L-1 inhibitor, or CTLA-4 inhibitor.
36 . The composition of claim 35 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor.
37 . The composition of claim 36 , wherein the PD-1 inhibitor is nivolumab.
38 . The composition of claim 36 , wherein the PD-1 inhibitor is pembrolizumab.
39 . The composition of claim 36 , wherein the PD-1 inhibitor is pidiluzimab.
40 . The composition of claim 35 , wherein the immune checkpoint inhibitor is a PD-L-1 inhibitor.
41 . The composition of claim 40 , wherein the PD-L-1 inhibitor is avelumab.
42 . The composition of claim 40 , wherein the PD-L-1 inhibitor is durvalumab.
43 . The composition of claim 35 , wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor.
44 . The composition of claim 43 , wherein the CTLA-4 inhibitor is an anti-CTLA-4 antibody.
45 . The composition of claim 43 , wherein the CTLA-4 inhibitor is ipilimumab.
46 . The composition of claim 43 , wherein the CTLA-4 inhibitor is tremelimumab.
47 . A pharmaceutical composition comprising the composition of any one of claims 1 - 46 , further comprising a pharmaceutically acceptable excipient.
48 . The pharmaceutical composition of claim 47 , wherein the pharmaceutical composition is formulated for oral delivery.
49 . The pharmaceutical composition of claim 47 , wherein the pharmaceutical composition is formulated for rectal delivery.
50 . The pharmaceutical composition of any one of claims 47 - 49 , wherein the pharmaceutical composition is formulated for delivery to the intestine.
51 . The pharmaceutical composition of any one of claims 47 - 50 , wherein the pharmaceutical composition is formulated for delivery to the colon.
52 . The pharmaceutical composition of any one of claims 47 - 51 , wherein the pharmaceutical composition is administered as one dose.
53 . The pharmaceutical composition of any one of claims 47 - 51 , wherein the pharmaceutical composition is administered as multiple doses.
54 . The pharmaceutical composition of claim 52 or 53 , wherein each dose comprises the administration of multiple capsules.
55 . A food product comprising the composition of any one of claims 1 - 46 and a nutrient.
56 . A method for treating cancer in a subject, the method comprising administering to the subject the composition of any one of claims 1 - 54 or the food product of claim 55 in an effective amount to treat the cancer.
57 . The method of claim 56 , wherein the cancer is carcinoma, glioma, mesothelioma, melanoma, lymphoma, leukemia, adenocarcinoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, multiple myeloma, prostate cancer, Burkitt's lymphoma, head and neck cancer, colon cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, cancer of the esophagus, stomach cancer, pancreatic cancer, hepatobiliary cancer, cancer of the gallbladder, cancer of the small intestine, rectal cancer, kidney cancer, bladder cancer, prostate cancer, penile cancer, urethral cancer, testicular cancer, vaginal cancer, uterine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, pancreatic endocrine cancer, carcinoid cancer, bone cancer, skin cancer, retinoblastomas, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, multicentric Castleman's disease, AIDS-associated primary effusion lymphoma, neuroectodermal tumors, or rhabdomyosarcoma.
58 . The method of claim 57 , wherein the cancer is prostate cancer, bladder cancer, non-small cell lung cancer, urothelial carcinoma, melanoma, or renal cell carcinoma.
59 . The method of any one of claims 56 - 58 , wherein an antibiotic is administered prior to the administration of any one of the compositions.
60 . The method of any one of claims 56 - 59 , wherein the subject is human.
61 . The method of any one of claims 56 - 60 , wherein the composition is administered to the subject more than once.
62 . The method of any one of claims 56 - 61 , wherein the composition is administered to the subject by oral administration.
63 . The method of any one of claims 56 - 61 , wherein the composition is administered to the subject by rectal administration.
64 . The method of any one of claims 56 - 63 , further comprising administering an antibiotic to the subject prior to administration of any one of the compositions or food products.
65 . The method of any one of claims 55 - 64 , wherein any one of the compositions or food products is administered to the subject in multiple doses.
66 . The method of claim 65 , wherein if one or more bacterial strains of the compositions colonize the subject to a level above a threshold level, no further compositions or food products are administered to the subject.
67 . The method of claim 66 , wherein if the compositions induce a CD8+ T cell response above a threshold level, no further compositions or food products are administered to the subject.
68 . A method of treating colitis associated with checkpoint inhibitor therapy in a subject, comprising administering to the subject a therapeutically effective amount of the composition of any one of claims 1 - 54 or the food product of claim 55 .
69 . The method of claim 68 , wherein the subject is human.
70 . The method of claim 68 or 69 , wherein the composition is administered to the subject more than once.
71 . The method of any one of claims 68 - 70 , wherein the composition is administered to the subject by oral administration.
72 . The method of any one of claims 68 - 70 , wherein the composition is administered to the subject by rectal administration.
73 . The method of any one of claims 68 - 72 , further comprising administering an antibiotic to the subject prior to administration of any one of the compositions or food products.
74 . The method of any one of claims 68 - 73 , wherein any one of the compositions or food products is administered to the subject in multiple doses.
75 . The method of claim 74 , wherein if one or more bacterial strains of the compositions colonize the subject to a level above a threshold level, no further compositions or food products are administered to the subject.
76 . The method of claim 74 , wherein if the compositions induce a CD8+ T cell response above a threshold level, no further compositions or food products are administered to the subject.
77 . A method for colonizing a microbiome of a subject, the method comprising administering to the subject a composition of any one of claims 1 - 54 or the food product of claim 55 in an effective amount to colonize the microbiome.
78 . The method of claim 77 , wherein the subject is human.
79 . The method of claim 77 or 78 , wherein the composition is administered to the subject more than once.
80 . The method of any one of claims 77 - 79 , wherein the composition is administered to the subject by oral administration.
81 . The method of any one of claims 77 - 79 , wherein the composition is administered to the subject by rectal administration.
82 . The method of any one of claims 77 - 81 , further comprising administering an antibiotic to the subject prior to administration of any one of the compositions or food products.
83 . The method of any one of claims 77 - 82 , wherein any one of the compositions or food products is administered to the subject in multiple doses.
84 . The method of claim 83 , wherein if one or more bacterial strains of the compositions colonize the subject to a level above a threshold level, no further compositions or food products are administered to the subject.
85 . The method of claim 83 , wherein if the compositions induce a CD8+ T cell response above a threshold level, no further compositions or food products are administered to the subject.
86 . A method for restoring a microbiome in a subject, the method comprising administering to the subject a composition of any one of claims 1 - 54 or the food product of claim 55 in an effective amount to restore the microbiome in the subject.
87 . The method of claim 86 , wherein the subject has not undergone a dysbiosis inducing event.
88 . The method of claim 86 or 87 , wherein the subject has not had an infectious disease.
89 . The method of any one of claims 86 - 88 , wherein the subject has not been treated with an antibiotic.
90 . The method of claim 89 , wherein the subject has undergone a dysbiosis inducing event.
91 . The method of claim 90 , wherein the dysbiosis inducing event is treatment with one or more antibiotic.
92 . The method of any one of claims 86 - 91 , wherein the subject is human.
93 . The method of any one of claims 86 - 92 , wherein the composition is administered to the subject more than once.
94 . The method of any one of claims 86 - 93 , wherein the composition is administered to the subject by oral administration.
95 . The method of any one of claims 86 - 93 , wherein the composition is administered to the subject by rectal administration.
96 . The method of any one of claims 86 - 95 , further comprising administering an antibiotic to the subject prior to administration of any one of the compositions or food products.
97 . The method of any one of claims 86 - 96 , wherein any one of the compositions or food products is administered to the subject in multiple doses.
98 . The method of claim 97 , wherein if one or more bacterial strains of the compositions colonize the subject to a level above a threshold level, no further compositions or food products are administered to the subject.
99 . The method of claim 97 , wherein if the compositions induce a CD8+ T cell response above a threshold level, no further compositions or food products are administered to the subject.